{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:45:04Z","timestamp":1792763104192,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There is a vast number of screening studies described in the literature from the beginning of the twenty-first century to the present day. Many of these studies are related to the estimation of Fabry disease (FD) morbidity among patients from high-risk groups, including adult patients with hypertrophic cardiomyopathy (HCM) and left ventricular hypertrophy (LVH). These studies show diverse detection frequencies (0\u201312%) depending on the methodology. Our study is the only example of large-scale selective FD screening based on the implementation of next-generation sequencing technology (NGS) as a first-level test to estimate FD morbidity in the Russian population over 18\u00a0years of age burdened with HCM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study included 1009 patients (578 males and 431 females), with a median age of 50\u00a0years, who were diagnosed with HCM according to current clinical guidelines. In the first stage of screening, all patients underwent molecular genetic testing (NGS method) of target regions. These regions included the coding sequences of 17 genes and mutations that can lead to the development of HCM. Lysosomal globotriaosylsphingosine (lyso-Gb3) concentrations and \u03b1-galactosidase A (\u03b1-gal A) enzyme activity were measured in the second stage of screening to reveal pathogenic or likely pathogenic variants in the <jats:italic>GLA<\/jats:italic> gene.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We revealed 8 (0.8%) patients (3 (37.5%) males and 5 (62.5%) females) with an average age of 59\u2009\u00b1\u200913.3\u00a0years who had pathogenic, likely pathogenic variants and variants of uncertain significance (VUS) in the <jats:italic>GLA<\/jats:italic> gene (NM_000169.2) as a result of selective screening of 1009 Russian patients with HCM. FD was confirmed via biochemical tests in a male with the pathogenic variant c.902G\u2009&gt;\u2009A, p.R301Q as well as in two females with likely pathogenic variants c.897C\u2009&gt;\u2009A, p.D299E and c.1287_1288dup, p.*430Fext*?. These tests showed reduced enzymatic activity and increased substrate concentration. However, a female with the pathogenic variant c.416A\u2009&gt;\u2009G, p.N139S and with normal enzymatic activity only had increased substrate concentrations. The revealed nucleotide variants and high values of biochemical indicators (lyso-Gb3) in these 4 patients allowed us to estimate the FD diagnosis among 1009 Russian patients with HCM. Mild extracardiac manifestations were observed in these four patients; however, both biochemical values within the reference range in females with the c.971T\u2009&gt;\u2009G, p.L324W (VUS) variant. \u03b1-gal A activity and lyso-Gb3 concentrations were also within the normal range in two males with hemizygous variants, c.546T\u2009&gt;\u2009C, p.D182D and c.640-794_640-791del (we regarded them as VUS), and in one female with the c.427G\u2009&gt;\u2009A, p.A143T variant (with conflicting interpretations of pathogenicity).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The prevalence rate of FD among 1,009 adult Russian patients with HCM was 0.4%. We recommend FD screening among adult patients of both sexes with HCM and an undefined genetic cause via NGS method with subsequent analysis of \u03b1-gal A activity and lyso-Gb3 concentration in patients with pathogenic, likely pathogenic variants, and VUS. This strategy identifies patients with an atypical form of FD that is characterized by high residual activity of \u03b1-gal A, low concentrations of lyso-Gb3, and minor extracardiac manifestations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02319-4","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T11:05:41Z","timestamp":1652699141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4885-4171","authenticated-orcid":false,"given":"K.","family":"Savostyanov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pushkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Zhanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mazanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Trufanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pakhomov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Alexeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sladkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Asanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fisenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"2319_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.21542\/gcsp.2018.36","volume":"3","author":"M Akhtar","year":"2018","unstructured":"Akhtar M, Elliott P. The genetics of hypertrophic cardiomyopathy. Glob Cardiol Sci Pract 2018. 2018;3:36. https:\/\/doi.org\/10.21542\/gcsp.2018.36.","journal-title":"Glob Cardiol Sci Pract 2018"},{"issue":"11","key":"2319_CR2","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/gim.2014.205","volume":"17","author":"AA Alfares","year":"2015","unstructured":"Alfares AA, Kelly MA, McDermott G, Funke BH, et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med. 2015;17(11):880\u20138. https:\/\/doi.org\/10.1038\/gim.2014.205.","journal-title":"Genet Med"},{"issue":"4","key":"2319_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMoa033349","volume":"352","author":"M Arad","year":"2005","unstructured":"Arad M, Maron BJ, Gorham JM, Johnson WH Jr, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med. 2005;352(4):362\u201372. https:\/\/doi.org\/10.1056\/NEJMoa033349.","journal-title":"N Engl J Med"},{"key":"2319_CR4","first-page":"185","volume":"466","author":"C Auray-Blais","year":"2017","unstructured":"Auray-Blais C, Lavoie P, Boutin M, et al. Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation. ClinChimActa. 2017;466:185\u201393.","journal-title":"ClinChimActa"},{"issue":"4","key":"2319_CR5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/cge.13694","volume":"97","author":"S Balendran","year":"2020","unstructured":"Balendran S, Oliva P, Sansen S, Mechtler TP, et al. Diagnostic strategy for females suspected of Fabry disease. Clin Genet. 2020;97(4):655\u201360. https:\/\/doi.org\/10.1111\/cge.13694.","journal-title":"Clin Genet"},{"issue":"1","key":"2319_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13023-019-1291-2","volume":"15","author":"J Bevilacqua","year":"2020","unstructured":"Bevilacqua J, Guecaimburu E, Perna A, et al. The Latin American experience with a next generation sequencing genetic panel for recessive limb-girdle muscular weakness and Pompe disease. Orphanet J Rare Dis. 2020;15(1):11.","journal-title":"Orphanet J Rare Dis"},{"key":"2319_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","volume":"10","author":"M Biegstraaten","year":"2015","unstructured":"Biegstraaten M, Arngr\u00edmsson R, Barbey F, Boks L, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36. https:\/\/doi.org\/10.1186\/s13023-015-0253-6.","journal-title":"Orphanet J Rare Dis"},{"key":"2319_CR8","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for illumina sequence data. Bioinformatics. 2014;30:2114\u201320.","journal-title":"Bioinformatics"},{"issue":"2","key":"2319_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.21037\/cdt.2020.01.12","volume":"10","author":"J Bonaventura","year":"2020","unstructured":"Bonaventura J, Norambuena P, Vot\u00fdpka P, Hn\u00e1tov\u00e1 H, et al. Patients with hypertrophic obstructive cardiomyopathy after alcohol septal ablation have favorable long-term outcome irrespective of their genetic background. Cardiovasc Diagn Ther. 2020;10(2):193\u2013200. https:\/\/doi.org\/10.21037\/cdt.2020.01.12.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"21","key":"2319_CR10","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brady","year":"1967","unstructured":"Brady RO, Gal AE, Bradley RM, Martensson E, et al. Enzymatic defect in Fabry\u2019s disease. Ceramidetrihexosidase Deficiency N Engl J Med. 1967;276(21):1163\u20137. https:\/\/doi.org\/10.1056\/NEJM196705252762101.","journal-title":"Ceramidetrihexosidase Deficiency N Engl J Med"},{"issue":"7","key":"2319_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/qjmed\/hct024","volume":"108","author":"M Brady","year":"2015","unstructured":"Brady M, Montgomery E, Brennan P, Mohindra R, Sayer JA. Diagnosing Fabry disease\u2013delays and difficulties within discordant siblings. QJM. 2015;108(7):585\u201390. https:\/\/doi.org\/10.1093\/qjmed\/hct024.","journal-title":"QJM"},{"key":"2319_CR12","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/01.CIR.0000139847.74101.03","volume":"110","author":"C Chimenti","year":"2004","unstructured":"Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation. 2004;110:1047\u201353.","journal-title":"Circulation"},{"key":"2319_CR13","unstructured":"Clinical Guidelines. Hypertrophic cardiomyopathy. Moscow, 2020. https:\/\/scardio.ru\/content\/Guidelines\/2020\/Clinic_rekom_Kardiomiopatiya.pdf. (in Russ.)"},{"key":"2319_CR14","volume-title":"The online metabolic and molecular bases of inherited diseases","author":"RJ Desnick","year":"2014","unstructured":"Desnick RJ, Ioannou YA, Eng CM. A-galactosidase a deficiency: Fabry disease. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, editors. The online metabolic and molecular bases of inherited diseases. New York: McGraw-Hill; 2014."},{"key":"2319_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/jmedgenet-2017-105080","volume":"55","author":"D Doheny","year":"2018","unstructured":"Doheny D, Srinivasan R, Pagant S, Chen B, Yasuda M, Desnick RJ. Fabry disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995\u20132017. J Med Genet. 2018;55:261\u20138. https:\/\/doi.org\/10.1136\/jmedgenet-2017-105080.","journal-title":"J Med Genet"},{"issue":"12","key":"2319_CR16","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.3390\/ijms19123726","volume":"19","author":"G Duro","year":"2018","unstructured":"Duro G, Zizzo C, Cammarata G, Burlina A, et al. Mutations in the GLA gene and LysoGb3: is it really Anderson-Fabry disease? Int J Mol Sci. 2018;19(12):3726. https:\/\/doi.org\/10.3390\/ijms19123726.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2319_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/BF01606034","volume":"417","author":"M Elleder","year":"1990","unstructured":"Elleder M, Bradov\u00e1 V, Sm\u00edd F, Bud\u0115s\u00ednsk\u00fd M, et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry\u2019s disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol. 1990;417(5):449\u201355. https:\/\/doi.org\/10.1007\/BF01606034.","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"issue":"23","key":"2319_CR18","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1136\/heartjnl-2011-300364","volume":"97","author":"P Elliott","year":"2011","unstructured":"Elliott P, Baker R, Pasquale F, Quarta G, et al. ACES study group. Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey. Heart. 2011;97(23):1957\u201360. https:\/\/doi.org\/10.1136\/heartjnl-2011-300364.","journal-title":"Heart"},{"issue":"4","key":"2319_CR19","doi-asserted-by":"publisher","first-page":"444","DOI":"10.6002\/ect.2019.0279","volume":"18","author":"S Erdogmus","year":"2020","unstructured":"Erdogmus S, Kutlay S, Kumru G, Ors Sendogan D, et al. Fabry disease screening in patients with kidney transplant: a single-center study in Turkey. Exp Clin Transplant. 2020;18(4):444\u20139. https:\/\/doi.org\/10.6002\/ect.2019.0279.","journal-title":"Exp Clin Transplant"},{"key":"2319_CR20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.7150\/ijms.14997","volume":"13","author":"M Gaggl","year":"2016","unstructured":"Gaggl M, Lajic N, Heinze G, et al. Screening for Fabry disease by urinary globotriaosylceramide isoforms measurement in patients with left ventricular hypertrophy. Int J Med Sci. 2016;13:340\u20136.","journal-title":"Int J Med Sci"},{"key":"2319_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/hrt.2010.200188","volume":"97","author":"AA Hag\u00e8ge","year":"2011","unstructured":"Hag\u00e8ge AA, Caudron E. Damy T et al Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study. Heart. 2011;97:131\u20136.","journal-title":"Heart"},{"key":"2319_CR22","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3389\/fneur.2018.00336","volume":"9","author":"L Hauth","year":"2018","unstructured":"Hauth L, Kerstens J, Yperzeele L, Eyskens F, et al. Galactosidase alpha p.A143T variant Fabry disease may result in a phenotype with multifocal microvascular cerebral involvement at a young age. Front Neurol. 2018;9:336. https:\/\/doi.org\/10.3389\/fneur.2018.00336.","journal-title":"Front Neurol"},{"key":"2319_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/eurjhf\/hfq073","volume":"12","author":"O Havndrup","year":"2010","unstructured":"Havndrup O, Christiansen M, Stoevring B, et al. Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women. Eur J Heart Fail. 2010;12:535\u201340. https:\/\/doi.org\/10.1093\/eurjhf\/hfq073.","journal-title":"Eur J Heart Fail"},{"key":"2319_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1750-1172-9-96","volume":"9","author":"TR Hsu","year":"2014","unstructured":"Hsu TR, Sung SH, Chang FP, Yang CF, et al. Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset Fabry mutation (IVS4 + 919G > A). Orphanet J Rare Dis. 2014;9:96. https:\/\/doi.org\/10.1186\/1750-1172-9-96.","journal-title":"Orphanet J Rare Dis"},{"key":"2319_CR25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13023-017-0722-1","volume":"12","author":"K Johnson","year":"2017","unstructured":"Johnson K, T\u00f6pf A, Bertoli M, et al. Identification of GAA variants through whole exome sequencing targeted to a cohort of 606 patients with unexplained limb-girdle muscle weakness. Orphanet J Rare Dis. 2017;12:173. https:\/\/doi.org\/10.1186\/s13023-017-0722-1.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2319_CR26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","volume":"130","author":"C Kampmann","year":"2008","unstructured":"Kampmann C, Linhart A, Baehner F, Palecek T, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol. 2008;130(3):367\u201373. https:\/\/doi.org\/10.1016\/j.ijcard.2008.03.007.","journal-title":"Int J Cardiol"},{"issue":"7","key":"2319_CR27","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2019.34.e63","volume":"34","author":"WS Kim","year":"2019","unstructured":"Kim WS, Kim HS, Shin J, et al. Prevalence of Fabry Disease in Korean Men with Left Ventricular Hypertrophy. J Korean Med Sci. 2019;34(7): e63. https:\/\/doi.org\/10.3346\/jkms.2019.34.e63.","journal-title":"J Korean Med Sci"},{"issue":"3","key":"2319_CR28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.15690\/vsp.v14i3.1369","volume":"14","author":"LM Kuzenkova","year":"2015","unstructured":"Kuzenkova LM, Namazova-Baranova LS, Podkletnova TV, Gevorkyan AK, et al. Fabry disease: symptoms in children and teenagers. Voprosy Sovremennoj Pediatrii. 2015;14(3):341\u20138. https:\/\/doi.org\/10.15690\/vsp.v14i3.1369.","journal-title":"Voprosy Sovremennoj Pediatrii"},{"issue":"1","key":"2319_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13023-016-0441-z","volume":"11","author":"M Lenders","year":"2016","unstructured":"Lenders M, Weidemann F, Kurschat C, Canaan-K\u00fchl S, et al. Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant. Orphanet J Rare Dis. 2016;11(1):54. https:\/\/doi.org\/10.1186\/s13023-016-0441-z.","journal-title":"Orphanet J Rare Dis"},{"key":"2319_CR30","unstructured":"Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. 2013. arXiv: 1303.3997v2 [q-bio.GN]."},{"issue":"5","key":"2319_CR31","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","volume":"2","author":"HY Lin","year":"2009","unstructured":"Lin HY, Chong KW, Hsu JH, Yu HC, et al. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet. 2009;2(5):450\u20136. https:\/\/doi.org\/10.1161\/CIRCGENETICS.109.862920.","journal-title":"Circ Cardiovasc Genet"},{"key":"2319_CR32","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","volume":"28","author":"A Linhart","year":"2007","unstructured":"Linhart A, Kampmann C, Zamorano JL, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J. 2007;28:1228\u201335.","journal-title":"Eur Heart J"},{"issue":"8","key":"2319_CR33","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1093\/ndt\/gfg194","volume":"18","author":"GE Linthorst","year":"2003","unstructured":"Linthorst GE, Hollak CE, Korevaar JC, Van Manen JG, et al. alpha-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease. Nephrol Dial Transplant. 2003;18(8):1581\u20134. https:\/\/doi.org\/10.1093\/ndt\/gfg194.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"2319_CR34","doi-asserted-by":"publisher","first-page":"e1003632","DOI":"10.1371\/journal.pgen.1003632","volume":"9","author":"J Lukas","year":"2013","unstructured":"Lukas J, Giese AK, Markoff A, Grittner U, et al. Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in Fabry disease. PLoS Genet. 2013;9(8):e1003632. https:\/\/doi.org\/10.1371\/journal.pgen.1003632.","journal-title":"PLoS Genet"},{"key":"2319_CR35","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","volume":"121","author":"AJ Marian","year":"2017","unstructured":"Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121:749\u201370. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311059.","journal-title":"Circ Res"},{"key":"2319_CR36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/gim.2018.31","volume":"21","author":"H Maruyama","year":"2019","unstructured":"Maruyama H, Miyata K, Mikame M, et al. Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis. Genet Med. 2019;21:44\u201352.","journal-title":"Genet Med"},{"issue":"8","key":"2319_CR37","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015473","volume":"9","author":"F Mazzarotto","year":"2020","unstructured":"Mazzarotto F, Olivotto I, Boschi B, Girolami F, et al. Contemporary insights into the genetics of hypertrophic cardiomyopathy: toward a new era in clinical testing? J Am Heart Assoc. 2020;9(8): e015473. https:\/\/doi.org\/10.1161\/JAHA.119.015473.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"2319_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000495886","volume":"141","author":"S Moiseev","year":"2019","unstructured":"Moiseev S, Fomin V, Savostyanov K, Pushkov A, et al. The prevalence and clinical features of Fabry disease in hemodialysis patients: Russian nationwide Fabry dialysis screening. Nephron. 2019;141(4):249\u201355. https:\/\/doi.org\/10.1159\/000495886.","journal-title":"Nephron"},{"issue":"10","key":"2319_CR39","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00431-017-2992-y","volume":"176","author":"LS Namazova-Baranova","year":"2017","unstructured":"Namazova-Baranova LS, Baranov AA, Pushkov AA, Savostyanov KV. Fabry disease in children: a federal screening programme in Russia. Eur J Pediatr. 2017;176(10):1385\u201391.","journal-title":"Eur J Pediatr"},{"issue":"1","key":"2319_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","volume":"7","author":"M Niemann","year":"2014","unstructured":"Niemann M, Rolfs A, St\u00f6rk S, Bijnens B, Breunig F, Beer M, Ertl G, Wanner C, Weidemann F. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet. 2014;7(1):8\u201316. https:\/\/doi.org\/10.1161\/CIRCGENETICS.113.000249.","journal-title":"Circ Cardiovasc Genet"},{"issue":"1","key":"2319_CR41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12881-016-0309-z","volume":"17","author":"D Oder","year":"2016","unstructured":"Oder D, Vergho D, Ertl G, Wanner C, Nordbeck P. Case report of a 45-year old female Fabry disease patient carrying two alpha-galactosidase A gene mutation alleles. BMC Med Genet. 2016;17(1):46. https:\/\/doi.org\/10.1186\/s12881-016-0309-z.","journal-title":"BMC Med Genet"},{"issue":"1","key":"2319_CR42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/prot.24708","volume":"83","author":"C Riera","year":"2015","unstructured":"Riera C, Lois S, Dom\u00ednguez C, Fernandez-Cadenas I, et al. Molecular damage in Fabry disease: characterization and prediction of alpha-galactosidase A pathological mutations. Proteins. 2015;83(1):91\u2013104. https:\/\/doi.org\/10.1002\/prot.24708.","journal-title":"Proteins"},{"issue":"5","key":"2319_CR43","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/europace\/euv079","volume":"18","author":"A Ruiz-Salas","year":"2016","unstructured":"Ruiz-Salas A, Garc\u00eda-Pinilla JM, Cabrera-Bueno F, Fern\u00e1ndez-Pastor J, et al. Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator. Europace. 2016;18(5):773\u20137. https:\/\/doi.org\/10.1093\/europace\/euv079.","journal-title":"Europace"},{"key":"2319_CR44","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","volume":"105","author":"B Sachdev","year":"2002","unstructured":"Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002;105:1407\u201311.","journal-title":"Circulation"},{"issue":"9","key":"2319_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239675","volume":"15","author":"C Sadasivan","year":"2020","unstructured":"Sadasivan C, Chow JTY, Sheng B, Chan DKH, et al. Screening for Fabry disease in patients with unexplained left ventricular hypertrophy. PLoS ONE. 2020;15(9): e0239675. https:\/\/doi.org\/10.1371\/journal.pone.0239675.","journal-title":"PLoS ONE"},{"issue":"3","key":"2319_CR46","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.nmd.2013.11.006","volume":"24","author":"A Sagnelli","year":"2014","unstructured":"Sagnelli A, Savoiardo M, Marchesi C, Morandi L, et al. Adult polyglucosan body disease in a patient originally diagnosed with Fabry\u2019s disease. Neuromuscul Disord. 2014;24(3):272\u20136. https:\/\/doi.org\/10.1016\/j.nmd.2013.11.006.","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"2319_CR47","first-page":"784","volume":"47","author":"H Sakuraba","year":"1990","unstructured":"Sakuraba H, Oshima A, Fukuhara Y, Shimmoto M, et al. Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet. 1990;47(5):784\u20139.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"2319_CR48","doi-asserted-by":"publisher","first-page":"242","DOI":"10.15690\/vramn872","volume":"72","author":"KV Savostyanov","year":"2017","unstructured":"Savostyanov KV, Namazova-Baranova LS, Basargina EN, Vashakmadze ND, et al. The new genome variants in Russian children with genetically determined cardiomyopathies revealed with massive parallel sequencing. Ann Russ Acad Med Sci. 2017;72(4):242\u201353. https:\/\/doi.org\/10.15690\/vramn872.","journal-title":"Ann Russ Acad Med Sci."},{"issue":"2","key":"2319_CR49","first-page":"S130","volume":"126","author":"K Savostyanov","year":"2019","unstructured":"Savostyanov K, Pushkov A, Mazanova N, Pak L, Kuzenkova L, Podkletnova T, Pakhomov A, Sukhozhenko A, Moiseev S. Lyso-Gb3 is as a primary biomarker for fabry disease screening among high-risk contingents. Mol Genet Metab. 2019;126(2):S130\u20131.","journal-title":"Mol Genet Metab"},{"key":"2319_CR50","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/gim.2017.175","volume":"20","author":"R Schiffmann","year":"2018","unstructured":"Schiffmann R, Swift C, McNeill N, et al. Low frequency of Fabry disease in patients with common heart disease. Genet Med. 2018;20:754\u20139. https:\/\/doi.org\/10.1038\/gim.2017.175.","journal-title":"Genet Med"},{"issue":"4","key":"2319_CR51","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","volume":"52","author":"BE Smid","year":"2015","unstructured":"Smid BE, van der Tol L, Biegstraaten M, Linthorst GE, et al. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease. J Med Genet. 2015;52(4):262\u20138. https:\/\/doi.org\/10.1136\/jmedgenet-2014-102872.","journal-title":"J Med Genet"},{"issue":"1","key":"2319_CR52","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31\u201340. https:\/\/doi.org\/10.1086\/504601.","journal-title":"Am J Hum Genet"},{"issue":"9","key":"2319_CR53","doi-asserted-by":"publisher","first-page":"289","DOI":"10.4330\/wjc.v2.i9.289","volume":"2","author":"KI Stroumpoulis","year":"2010","unstructured":"Stroumpoulis KI, Pantazopoulos IN, Xanthos TT. Hypertrophic cardiomyopathy and sudden cardiac death. World J Cardiol. 2010;2(9):289\u201398. https:\/\/doi.org\/10.4330\/wjc.v2.i9.289.","journal-title":"World J Cardiol"},{"issue":"Suppl 9","key":"2319_CR54","first-page":"A34","volume":"102","author":"H Sulaiman","year":"2016","unstructured":"Sulaiman H, Finegan E, Tisdall RA, Murphy R. Prevalence of Fabry disease among patients diagnosed hypertrophic cardiomyopathy and unexplained left ventricular hypertrophy in St. James hospital (2013\u20132015). Heart. 2016;102(Suppl 9):A34.","journal-title":"Heart"},{"issue":"1","key":"2319_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","volume":"51","author":"L van der Tol","year":"2014","unstructured":"van der Tol L, Smid BE, Poorthuis BJ, et al. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet. 2014;51(1):1\u20139. https:\/\/doi.org\/10.1136\/jmedgenet-2013-101857.","journal-title":"J Med Genet"},{"issue":"8","key":"2319_CR56","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/heartjnl-2019-315933","volume":"106","author":"K Valtola","year":"2020","unstructured":"Valtola K, Nino-Quintero J, Hedman M, Lottonen-Raikaslehto L, et al. Cardiomyopathy associated with the Ala143Thr variant of the \u03b1-galactosidase Agene. Heart. 2020;106(8):609\u201315. https:\/\/doi.org\/10.1136\/heartjnl-2019-315933.","journal-title":"Heart"},{"issue":"3","key":"2319_CR57","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.amjms.2021.01.009","volume":"362","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Sun Y, Tian T, Wang TJ, et al. Prevalence and clinical characteristics of Fabry disease in Chinese patients with hypertrophic cardiomyopathy. Am J Med Sci. 2021;362(3):260\u20137. https:\/\/doi.org\/10.1016\/j.amjms.2021.01.009.","journal-title":"Am J Med Sci"},{"key":"2319_CR58","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2169\/internalmedicine.0959-18","volume":"58","author":"S Yamamoto","year":"2019","unstructured":"Yamamoto S, Nagasawa T, Sugimura K, Kanno A, et al. Clinical diversity in patients with Anderson-Fabry disease with the R301Q mutation. Intern Med. 2019;58:603\u20137. https:\/\/doi.org\/10.2169\/internalmedicine.0959-18.","journal-title":"Intern Med"},{"issue":"88","key":"2319_CR59","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cjca.2017.04.015","volume":"33","author":"H Yogasundaram","year":"2017","unstructured":"Yogasundaram H, Kim D, Oudit O, Thompson RB, Weidemann F, Oudit GY. Clinical features, diagnosis, and management of patients with anderson-fabry cardiomyopathy. Can J Cardiol. 2017;33(88):3\u2013897. https:\/\/doi.org\/10.1016\/j.cjca.2017.04.015.","journal-title":"Can J Cardiol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02319-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02319-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02319-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T11:12:36Z","timestamp":1652699556000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02319-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2319"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02319-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"assertion":[{"value":"13 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project has been conducted within a diagnostic setting, and as a second step, utilized de-identified data and samples. Thus, this did not require independent ethics committee approval in our jurisdiction. All patients signed written informed consent forms before the screening study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest. The funders had no role in the study design, in the data collection, analyses, and interpretation, in the writing of the manuscript, or in the decision to publish the results.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}